List of Excipients in Branded Drug AVELOX

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Physicians Total Care Inc	AVELOX	moxifloxacin hydrochloride	54868-4367	CELLULOSE, MICROCRYSTALLINE
Physicians Total Care Inc	AVELOX	moxifloxacin hydrochloride	54868-4367	CROSCARMELLOSE SODIUM
Physicians Total Care Inc	AVELOX	moxifloxacin hydrochloride	54868-4367	FERRIC OXIDE RED
Physicians Total Care Inc	AVELOX	moxifloxacin hydrochloride	54868-4367	HYPROMELLOSES

AVELOX Excipient Strategy and Commercial Opportunities for Moxifloxacin

Last updated: August 6, 2026

Avelox is the former Bayer brand for moxifloxacin hydrochloride, a fourth-generation fluoroquinolone supplied primarily as a 400 mg oral tablet and a 400 mg/250 mL intravenous solution. Its core composition-of-matter and regulatory exclusivities have expired, leaving commercial value in generic supply, hospital formulations, excipient optimization, packaging, and differentiated delivery rather than in the original brand.

The strongest opportunities are low-cost oral products, ready-to-use intravenous presentations, preservative-free or low-excipient hospital products, and contract manufacturing. New products must address fluoroquinolone safety restrictions, antibiotic-stewardship policies, and intense generic price competition.

What is Avelox and which dosage forms use moxifloxacin?

Avelox contains moxifloxacin hydrochloride, equivalent to 400 mg of moxifloxacin. The product was approved in the United States for selected bacterial infections, including community-acquired pneumonia, acute bacterial sinusitis, acute bacterial exacerbation of chronic bronchitis, skin and skin-structure infections, and intra-abdominal infections, subject to labeling limitations and resistance considerations.[1]

Product	Active ingredient	Strength	Route	Commercial relevance
Avelox tablets	Moxifloxacin hydrochloride	400 mg	Oral	Generic competition is extensive
Avelox injection	Moxifloxacin hydrochloride	400 mg/250 mL	Intravenous infusion	Hospital and institutional opportunity
Moxifloxacin generic tablets	Moxifloxacin hydrochloride	400 mg	Oral	Commodity-oriented market
Moxifloxacin ophthalmic products	Moxifloxacin hydrochloride	Usually 0.5%	Ophthalmic	Separate product category, not an Avelox equivalent

Avelox should not be confused with Vigamox, the ophthalmic moxifloxacin brand. Vigamox uses a different dosage form, administration route, formulation strategy, and regulatory product history.

What excipients are used in Avelox tablets?

The Avelox tablet formulation uses conventional immediate-release excipients. The U.S. prescribing information identifies lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, magnesium stearate, hypromellose, titanium dioxide, red ferric oxide, and polyethylene glycol among the inactive ingredients.[1]

Excipient	Likely functional role	Commercial and regulatory considerations
Lactose monohydrate	Diluent and tablet bulk	Creates a lactose-intolerance and dairy-derived excipient consideration
Microcrystalline cellulose	Diluent and compression aid	Supports tablet hardness and manufacturability
Croscarmellose sodium	Superdisintegrant	Controls tablet breakup and dissolution
Magnesium stearate	Lubricant	Excess levels can slow wetting and dissolution
Hypromellose	Film former	Provides coating strength and appearance
Titanium dioxide	Opacifier and colorant	Subject to jurisdiction-specific regulatory scrutiny
Red ferric oxide	Colorant	Supports product identification
Polyethylene glycol	Film-coating plasticizer or solvent aid	Affects coating flexibility and processing

The formulation is technically straightforward. The active ingredient has high potency at the 400 mg dose, and an immediate-release tablet does not require a complex modified-release matrix. The principal development challenge is matching dissolution, assay, impurities, tablet robustness, and bioequivalence while controlling cost.

How should a generic manufacturer optimize Avelox excipients?

A generic manufacturer should treat the product as a bioequivalence-sensitive immediate-release tablet rather than as a platform for unnecessary formulation complexity.

The main excipient strategy is to preserve rapid and reproducible drug release. Moxifloxacin is commonly formulated with a standard diluent-disintegrant-lubricant system. Changes to lactose grade, microcrystalline cellulose particle size, croscarmellose concentration, or magnesium stearate mixing time can alter disintegration and dissolution.

A practical development strategy has four priorities:

1. Use a robust direct-compression or dry-granulation process.
2. Minimize lubricant overmixing.
3. Select excipient grades with stable moisture and particle-size profiles.
4. Establish discriminatory dissolution methods before pivotal comparative studies.

Potential substitutions include lactose-free formulations using mannitol, anhydrous dibasic calcium phosphate, or additional microcrystalline cellulose. These substitutions may improve patient positioning but can affect tablet weight, hardness, friability, and dissolution.

The commercial value of a lactose-free Avelox-equivalent product is limited in a conventional generic channel because most purchasers prioritize price and supply continuity. It may have more value in hospital systems, specialty pharmacies, and markets with stronger excipient-labeling requirements.

What excipients are used in Avelox intravenous injection?

The intravenous product is a ready-to-use aqueous solution containing moxifloxacin hydrochloride in a 250 mL presentation. The formulation uses sodium chloride and water for injection, with pH adjustment as needed.[1]

The injectable strategy differs materially from the tablet strategy. The key quality attributes are:

• Chemical stability over shelf life.
• Control of particulate matter.
• Sterility and endotoxin limits.
• Compatibility with infusion equipment.
• Container-closure integrity.
• Protection from excessive light exposure.
• Reliable administration over the labeled infusion period.

A ready-to-use 250 mL bag reduces pharmacy compounding requirements and may be commercially preferable to a concentrated vial. The tradeoff is higher freight cost, larger storage volume, and greater packaging complexity.

Generic manufacturers can pursue:

• Polyolefin bags instead of glass containers.
• Smaller institutional pack sizes where permitted.
• Improved overwraps for light protection.
• Barcoded unit-dose packaging.
• Terminally sterilized presentations when compatible with the formulation.
• Reduced-excipient solutions with tightly controlled pH and osmolality.

The strongest hospital value proposition is operational, not pharmacological. A product that reduces compounding steps, medication errors, and inventory handling can compete even when the active ingredient is otherwise commoditized.

What patents protect Avelox and its excipient formulation?

Avelox's principal patent protection was directed to moxifloxacin and related quinolone chemistry rather than to a commercially differentiated excipient system. The key U.S. composition-of-matter patent commonly associated with moxifloxacin is U.S. Patent No. 5,607,942, assigned to Bayer AG and related entities. Its effective patent term expired in 2014, subject to applicable patent-term calculations and regulatory adjustments.[2]

Protection category	Avelox position	Commercial impact
Active ingredient	Expired	No remaining composition-of-matter barrier in the U.S.
Oral tablet formulation	No material current barrier identified	Generic tablet development is open
Intravenous solution	No material current barrier identified	Generic IV competition is open
Method of use	Historical indications and label protections have expired or narrowed	Limited blocking value
Orange Book listing	No meaningful current Avelox patent barrier expected	Paragraph IV risk is largely historical
Excipient platform	No known broad proprietary platform central to Avelox	Low formulation-IP barrier

A simple substitution of inactive ingredients generally does not create durable patent protection. A formulation patent would need to claim a technically meaningful combination, stability advantage, delivery system, or manufacturing process. For a conventional 400 mg immediate-release tablet, the patentability threshold is difficult to meet without unexpected performance data.

What is the Orange Book status of Avelox?

Avelox is an old small-molecule product whose U.S. regulatory exclusivity and core patent protection have expired. The FDA Orange Book remains the relevant source for checking current NDA, patent, and exclusivity listings, but the commercial market is no longer protected by the original Avelox exclusivity structure.[3]

The original product had no biosimilar pathway because moxifloxacin is a small-molecule drug. Competitors file abbreviated new drug applications rather than biosimilar applications.

A generic applicant may use a Paragraph III certification where listed patent protection has expired or a Paragraph IV certification where it asserts that a listed patent is invalid, unenforceable, or not infringed. For Avelox, the practical importance of Paragraph IV litigation has declined because the core patent term has ended.

When did Avelox lose exclusivity?

Avelox lost meaningful U.S. market exclusivity after the expiration of its active-ingredient patent and the end of the applicable new chemical entity exclusivity period.

Event	Approximate timing	Effect
FDA approval of Avelox tablets	1999	Began branded U.S. commercialization
FDA approval of intravenous formulation	Early 2000s	Expanded hospital use
New chemical entity exclusivity	Ended approximately 2004	Allowed potential generic filing after the NCE period
Core moxifloxacin patent expiry	2014	Removed the main composition-of-matter barrier
Generic market development	Mid-2010s onward	Shifted value from exclusivity to cost and supply

The brand has no current exclusivity advantage comparable to an active patent-protected specialty product. Revenue exposure is therefore tied to prescription volume, institutional demand, contract pricing, and manufacturing efficiency.

What commercial opportunities remain for Avelox excipients?

The most credible opportunities are in product execution rather than new pharmacology.

Low-cost oral tablets

A manufacturer can compete through:

• High-yield compression.
• Dual-source excipient procurement.
• Consistent dissolution across manufacturing sites.
• Small, clearly differentiated packaging configurations.
• Reliable shortage prevention.
• Lactose-free or selected-colorant-free options.

Margins are likely to be narrow. The product is suitable for high-volume generic portfolios with existing oral solid-dose infrastructure.

Ready-to-use intravenous products

Hospital buyers may value a ready-to-administer moxifloxacin infusion if the supplier offers dependable delivery and competitive institutional pricing. A manufacturer can differentiate through:

• Bag materials compatible with common infusion systems.
• Reduced overwrap and packaging waste.
• Improved cold-chain and warehouse stability, where supported by data.
• Unit-level barcode compliance.
• Flexible case counts.
• Consistent supply during generic shortages.

The intravenous market generally requires stronger quality systems and higher working capital than tablets, but it can provide better customer retention.

Patient-oriented excipient variants

Potential variants include lactose-free tablets, alternative color systems, and formulations that avoid excipients restricted in particular jurisdictions. These products may support contracting with health systems that maintain excipient-specific formularies.

The commercial case must be tested against the cost of separate tooling, stability studies, artwork, regulatory filings, and inventory fragmentation. A variant that does not improve formulary access or patient adherence may not justify its development cost.

Contract manufacturing and private-label supply

Moxifloxacin is suitable for private-label and regional supply agreements because its formulation is established and the active ingredient is available from multiple API sources. The main barriers are:

• API impurity control.
• Nitrosamine and related impurity surveillance where applicable.
• Demonstrated bioequivalence.
• GMP compliance.
• Reliable validation across sites.
• Regulatory registration in each target market.

For smaller companies, licensing an approved dossier or partnering with an established generic manufacturer may be more efficient than building a new development program.

Which companies are challenging Avelox commercially?

The commercial field includes generic manufacturers with established fluoroquinolone portfolios, hospital suppliers, and regional pharmaceutical companies. Relevant competitors may include firms such as Sandoz, Teva, Viatris, Dr. Reddy's Laboratories, Cipla, Sun Pharmaceutical Industries, Hikma, Fresenius Kabi, and other regional suppliers, depending on jurisdiction and current marketing status.

Competition is not based solely on the number of approved ANDAs. A manufacturer needs active commercial distribution, dependable API sourcing, acceptable batch release performance, and institutional contracting capability.

For oral tablets, the market is usually price-led. For intravenous products, supplier reliability and operational convenience have greater weight. This creates a direct distinction between the two dosage forms:

Factor	Oral moxifloxacin	Intravenous moxifloxacin
Main buyer	Retail, mail-order, institutional pharmacy	Hospitals and health systems
Formulation complexity	Low to moderate	Moderate to high
Excipient differentiation	Limited	Packaging and solution attributes matter
Price pressure	Very high	High, but supply reliability matters
Main barrier	Bioequivalence and cost	Sterility, stability, packaging, logistics
Patent risk	Minimal	Minimal
Commercial upside	Volume-based	Contract and shortage-based

What generic launch risks exist for Avelox?

A generic launch faces limited patent risk but meaningful market and regulatory risk.

The principal risks are:

• Fluoroquinolone class warnings that reduce prescribing.
• Declining use for uncomplicated infections.
• Hospital antimicrobial-stewardship restrictions.
• Generic price erosion.
• API supply disruption.
• FDA review of manufacturing observations.
• Tablet dissolution failure after excipient changes.
• IV container-closure or particulate failures.
• Reimbursement pressure.
• Low return on investment for a single-product launch.

FDA safety communications have warned about disabling and potentially permanent adverse effects involving tendons, muscles, joints, nerves, and the central nervous system. The labeling also addresses QT prolongation, dysglycemia, aortic risks, and other class-related concerns.[4] These restrictions reduce the addressable market even though they do not eliminate clinical use.

A company should avoid positioning a new moxifloxacin product as a broad first-line antibiotic. Commercial messaging should focus on approved indications, appropriate stewardship, dosage-form availability, and supply reliability.

How strong is the Avelox patent estate?

The Avelox patent estate is weak as a current barrier to entry because the principal active-ingredient patent has expired and the product is a conventional small-molecule formulation.

Patent estate dimension	Assessment
Composition of matter	Expired
Formulation claims	Limited practical blocking value
Manufacturing claims	Potentially relevant only to specific processes
Method-of-use claims	Limited after long market history
Biosimilar protection	Not applicable
Generic substitution barrier	Low
Litigation exposure	Low relative to active protected drugs
Commercial defensibility	Based on cost, quality, supply, and contracts

A new formulation patent would need a defensible technical effect, such as materially improved stability, a novel infusion system, or a clinically relevant delivery advantage. Replacing one common diluent with another is unlikely to provide strong exclusionary value by itself.

What geographic markets offer the best opportunity?

The opportunity varies by route and regulatory environment.

The United States offers a mature generic market with strong purchasing pressure and an established regulatory pathway. Europe has broad generic availability and country-specific reimbursement dynamics. Emerging markets may offer higher unmet demand but require local registration, pricing adaptation, and protection against variable distribution quality.

For oral products, the best markets are those with:

• High generic substitution.
• Stable antibiotic procurement.
• Established API import channels.
• Low registration cost relative to expected volume.

For injectable products, the priority markets are those with:

• High inpatient utilization.
• Centralized hospital procurement.
• Demand for ready-to-use infusion bags.
• Recurrent shortages or limited supplier depth.

Geographic expansion should account for local restrictions on titanium dioxide, colorants, lactose labeling, infusion-container materials, and antimicrobial prescribing.

Key Takeaways

• Avelox is the former Bayer brand for moxifloxacin hydrochloride.
• The main products are 400 mg immediate-release tablets and 400 mg/250 mL intravenous infusion.
• Tablet excipients are conventional and include lactose, microcrystalline cellulose, croscarmellose sodium, magnesium stearate, hypromellose, titanium dioxide, red ferric oxide, and polyethylene glycol.
• The intravenous formulation relies on sodium chloride and water for injection, with controlled pH, sterility, stability, and packaging performance.
• Core patent and regulatory exclusivities have expired, leaving minimal current patent-based entry risk.
• The strongest commercial opportunities are generic supply, ready-to-use IV products, private-label manufacturing, and selected excipient variants.
• Oral products are primarily cost-driven. IV products offer more scope for operational differentiation.
• Fluoroquinolone safety warnings and antimicrobial stewardship materially constrain demand.
• Excipient changes can support product differentiation but rarely create strong patent protection without unexpected technical advantages.
• Commercial success depends more on manufacturing efficiency, regulatory execution, supply reliability, and institutional contracting than on proprietary formulation technology.

Frequently Asked Questions

Is Avelox still available as a brand-name drug?

Avelox has largely been displaced by generic moxifloxacin in the United States. Availability of the branded product varies by country and distribution channel.

Can a company patent a lactose-free moxifloxacin tablet?

A lactose-free formulation may be patentable only if it satisfies novelty, non-obviousness, and enablement requirements and demonstrates a meaningful technical advantage. A routine excipient substitution generally provides weak patent protection.

Does moxifloxacin have biosimilar competition?

No. Moxifloxacin is a small-molecule antibiotic. Competitors use generic drug applications, not biosimilar applications.

Is intravenous moxifloxacin more commercially attractive than oral moxifloxacin?

It can provide stronger differentiation through ready-to-use packaging, hospital contracts, and supply reliability. It also requires more demanding sterile manufacturing, validation, and logistics.

What is the main regulatory risk for a new moxifloxacin product?

The main risks are bioequivalence or dissolution failure for tablets, sterile-manufacturing and stability failure for injections, and reduced demand caused by fluoroquinolone safety restrictions and antimicrobial stewardship.

References

1. Bayer HealthCare Pharmaceuticals. (2011). Avelox (moxifloxacin hydrochloride) tablets and injection prescribing information. U.S. Food and Drug Administration labeling archive.

2. United States Patent and Trademark Office. (1997). U.S. Patent No. 5,607,942: Quinolone carboxylic acids. Washington, DC: U.S. Department of Commerce.

3. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugsatfda

4. U.S. Food and Drug Administration. (2018). FDA updates warnings for oral and injectable fluoroquinolone antibiotics due to disabling side effects. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers.